The limitations also include the inability to accurately mimic the complexity of AD pathology, including amyloid-beta plaque formation, tau tangles, and neuroinflammation, and differences in drug metabolism and pharmacokinetics, which can affect the efficacy and safety profiles of therapeutic candidates. This evidence concerns the gene MAPT and Alzheimer disease.